Monoclonal antibody · Kills target cells, directed at CD38 and multiple myeloma cells · developed by Janssen Biotech
Daratumumab is an IgG1κ human monoclonal antibody that binds CD38, a transmembrane glycoprotein on hematopoietic cells including myeloma cells. It kills CD38-expressing tumor cells through apoptosis induced by Fc-mediated cross-linking, complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity and phagocytosis, and it decreases CD38-positive regulatory T cells, B cells and myeloid-derived suppressor cells. It is studied in plasma cell disorders.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Sep 8, 2026). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07649525 | Phase 3 | Multiple Myeloma (MM) | Recruiting | JNJ |
| NCT07075510 | Phase 1/2 | Plasma Cell Disorder | Recruiting | JNJ |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Plasma Cell Disorder
Updated Nov 8, 2026. Something wrong or missing? Report it on the JNJ page.
See JNJ's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
JNJ catalysts and pipeline →